Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (252)
  2. Journal Article (103)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (4)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (381)
  2. Department of Medicine (381)
  3. Hematologic Malignancies Research (381)
  4. Hematologic Malignancies, Division of (381)
  5. Myeloma (381)
  6. Survivorship Research (225)

More Groups

People
  1. Hani Hassoun (202)
  2. Heather Landau (187)
  3. Sergio Giralt (185)
  4. David Chung (175)
  5. Neha Korde (174)
  6. Sham Mailankody (170)

More People

Years
  1. 2025 (12)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (41)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (12)

More Publications

Publishers
  1. American Society of Hematology (152)
  2. Elsevier Inc. (79)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (26)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (381)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma
    Review

    Firestone, R.; Lesokhin, A. M.; Usmani, S. Z.
    Blood Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients with relapsed/refractory multiple myeloma (RRMM): Subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: Pooled analysis from MagnetisMM Studies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; Leleu, X.; Karlin, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Cohort a of MagnetisMM-3
    Meeting Abstract

    Shay, G.; Bahlis, N.; Tomasson, M. H.; Mohty, M.; Niesvizky, R.; Nooka, A.; Manier, S.; Maisel, C.; Jethava, Y.; Martinez-Lopez, J.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial
    Journal Article

    Bahlis, N. J.; Costello, C. L.; Raje, N. S.; Levy, M. Y.; Dholaria, B.; Solh, M.; Tomasson, M. H.; Damore, M. A.; Jiang, S.; Basu, C.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results
    Journal Article

    Lesokhin, A. M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Miles Prince, H.; Niesvizky, R.; Rodrίguez-Otero, P.; Martinez-Lopez, J.; Koehne, G.; Touzeau, C.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
    Journal Article

    Coffey, D. G.; Maura, F.; Gonzalez-Kozlova, E.; Diaz-Mejia, J. J.; Luo, P.; Zhang, Y.; Xu, Y.; Warren, E. H.; Dawson, T.; Lee, B.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent
    Meeting Abstract

    Kumar, S.; Bachier, C. R.; Cavo, M.; Corradini, P.; Delforge, M.; Janowski, W.; Lesokhin, A. M.; Mina, R.; Paris, L.; Rosiñol, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save